Monitor for IND submission and Phase 1 trial initiation in 2027, which are the next key catalysts. The $6.1M cash runway is tight for a pre-revenue biotech, so watch for potential dilutive financing events.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $1.55entry
- T+1 · 3mo ago −4.52%α −4.77% · $1.48
- T+5 · 3mo ago +0.65%α +1.05% · $1.56
- T+20 · 2mo ago +18.71%α +19.77% · $1.84
- T+60 · 13d ago −21.61%α −21.13% · $1.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is expected to enter the clinic in 2027. The company reported cash of $6.1M as of June 30, 2026, with a runway to mid-2027. The filing is a routine business update with no new material financial data or clinical results, but the cash runway and pre-revenue status are notable risks for a $2M market cap company.
Key Facts
- Cash of $6.1M as of June 30, 2026, with runway to mid-2027.
- Lead program IM1240 (cappedCD3x5T4xNKG2A) expected to enter the clinic in 2027.
- Pre-IND meeting completed; IND submission planned for 2027.
- Second program IM1305 (cappedCD3xTROP2xNKG2A) in preclinical development.
- Market cap of $2M as of filing date.
Financial Impact
Cash of $6.1M provides runway to mid-2027; no revenue reported.
Risk Factors
- Cash runway only to mid-2027, requiring additional financing before clinical data.
- All programs are preclinical or early clinical, with no approved products or revenue.
- Low market cap ($2M) increases volatility and risk of delisting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-087226 |
| Document: ea0301142-6k_purple.htm | 0001213900-26-087226 |
| Document: 0001213900-26-087226-index-headers.html | 0001213900-26-087226 |
| Document: 0001213900-26-087226-index.html | 0001213900-26-087226 |
| Document: 0001213900-26-087226.txt | 0001213900-26-087226 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Viewing Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers